Cover Image
市場調查報告書

I型糖尿病的全球市場:2016∼2020年

Global Type 1 Diabetes Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 305743
出版日期 內容資訊 英文 80 Pages
訂單完成後即時交付
價格
Back to Top
I型糖尿病的全球市場:2016∼2020年 Global Type 1 Diabetes Market 2016-2020
出版日期: 2016年03月21日 內容資訊: 英文 80 Pages
簡介

I型糖尿病,是特徵為高血糖的自體免疫疾病。免疫系統對胰島素產活細胞活化,阻礙胰島素的生產生能力,破壞血糖體內平衡。型糖尿病只佔全糖尿病病例的5∼15%,而0∼15歲的兒童和未成年患病稱為幼發型糖尿病。全球I型糖尿病市場,預計2016∼2020年以年複合成長率8.05%擴大。

本報告提供全球I型糖尿病市場現狀與至2020年的成長預測,市場趨勢與課題,各地區趨勢,以及主要供應商簡介彙整。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 疾病概要

  • 簡介
  • 風險因素
  • 診斷
  • 管理
  • 流行病學
  • 經濟負擔

第6章 胰島素:概要

  • 產品系列
  • 全球人類用胰島素市場

第7章 開發平台分析

第8章 美國的報銷問題方案

第9章 市場情況

  • 全球糖尿病藥物市場
  • 全球I型糖尿病藥物市場
  • 波特的五力分析

第10章 各類藥物市場區隔

第11章 各地區市場區隔

  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第12章 推動市場的要素

第13章 促進要素的影響

第14章 市場課題

第15章 促進要素的影響與課題

第16章 市場趨勢

第17章 供應商環境

  • 競爭模式
  • 2015年的市場分析
  • Novo Nordisk
  • Sanofi
  • Eli Lilly
  • 其他值得注意的供應商

第18章 附錄

第19章 關於Technavio

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR9079

About Type 1 Diabetes Drugs

Diabetes, often referred to as diabetes mellitus, results in high blood glucose levels. Depending on the cause of development, it can be divided into three types:

  • Type 1 diabetes (or insulin-dependent diabetes mellitus): The pancreas do not produce the required amount of insulin in the body, leading to high blood glucose levels.
  • Type 2 diabetes (non-insulin-dependent diabetes mellitus): In this condition, though the body produces the required amount of insulin, the cells do not respond to it. This results in a high glucose level in the body.

Gestational diabetes: This condition occurs in pregnant women without any history of diabetes.

Type 1 diabetes is an autoimmune disorder characterized by high blood glucose levels. In this condition, the immune system is activated against insulin-producing cells. This condition hampers the body's ability to produce insulin and disrupts blood glucose homeostasis. Type 1 diabetes differs from a more prevalent form of diabetes mellitus, type 2 diabetes, wherein the insulin is produced inside the body. Type 1 diabetes accounts for only 5%-15% of the total diabetes cases. As the disease is more prevalent among children and adolescents aged 0-15 years, it was earlier known as juvenile diabetes. Type 1 diabetes management relies on providing symptomatic relief and improving the quality of life of people.

Technavio's analysts forecast the global type 1 diabetes drugs market to grow at a CAGR of 8.05% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global type 1 diabetes drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs and biosimilars used to treat and prevent type 1 diabetes.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Type 1 Diabetes Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Eli Lilly and Company
  • Novo Nordisk A/S
  • Sanofi SA

Other Prominent Vendors

  • Adocia
  • Astellas Pharma
  • AstraZeneca
  • Baxalta
  • BHV Pharma
  • Biocon
  • Biodel
  • Boehringer Ingelheim
  • CureDM
  • Dance Biopharm
  • Diamyd Therapeutics AB
  • Diasome Pharmaceuticals
  • DiaVac
  • Exsulin
  • Gan & Lee Pharmaceuticals
  • Generex Biotechnology
  • GlaxoSmithKline
  • ILTOO Pharma
  • Intrexon
  • Islet Sciences
  • Kamada
  • Kotobuki Pharmaceutical
  • Lexicon Pharmaceuticals
  • Living Cell Technologie
  • MacroGenics
  • MannKind Pharmaceuticals
  • Merck
  • Merrion Pharmaceutical
  • Oramed Pharmaceuticals
  • Osiris Therapeutics
  • Perle Biosciences
  • Pfizer
  • REGiMMUNE
  • Strongbridge Biopharma
  • Toleranzia
  • Tolerio
  • Xeris Pharmaceuticals
  • XOMA

Market driver

  • Increase in prevalence of type 1 diabetes
  • For a full, detailed list, view our report

Market challenge

  • Poor storage conditions and distribution policies for insulin
  • For a full, detailed list, view our report

Market trend

  • Awareness programs and initiatives
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Key buying criteria

PART 05: Disease overview

  • Introduction
  • Risk factors
  • Diagnosis
  • Management
  • Epidemiology
  • Economic burden

PART 06: Insulin: An overview

  • Product portfolio
  • Global human insulin market

PART 07: Pipeline analysis

  • Faster-acting insulin aspart (NN1218)
  • Farxiga/Forxiga
  • SAR342434
  • NN9211
  • LY2605541
  • Sotagliflozin
  • MK-1293
  • PRL001
  • Otelixizumab

PART 08: Reimbursement scenario in US

PART 09: Market landscape

  • Global diabetes drugs market
  • Global type 1 diabetes drugs market
  • Five forces analysis

PART 10: Market segmentation by drug class

  • Insulin
  • Others

PART 11: Geographical segmentation

  • Type 1 diabetes drugs market in Americas
  • Type 1 diabetes drugs market in EMEA
  • Type 1 diabetes drugs market in APAC

PART 12: Market drivers

  • Increase in prevalence of type 1 diabetes
  • Advances in insulin delivery technology
  • Rise in price of insulin drugs
  • Stringent regulatory conditions for biosimilar drugs
  • Promising drug pipeline

PART 13: Impact of drivers

PART 14: Market challenges

  • Side effects of current therapies
  • Fierce market competition
  • Poor storage conditions and distribution policies for insulin
  • Gap in nation-level diabetes management plans
  • Rising concerns in scientific community

PART 15: Impact of drivers and challenges

PART 16: Market trends

  • Development of drugs with novel mechanisms
  • Awareness programs and initiatives
  • Focus on emerging markets
  • Increase in academia-industry collaboration

PART 17: Vendor landscape

  • Competitive scenario
  • Market analysis 2015
  • Novo Nordisk
  • Sanofi
  • Eli Lilly
  • Other prominent vendors

PART 18: Appendix

  • List of abbreviations

PART 19: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Key buying criteria for type 1 diabetes drugs
  • Exhibit 03: Diagnostic test for diabetes based on blood sugar levels
  • Exhibit 04: Diagnostic test for diabetes based on glycated hemoglobin levels
  • Exhibit 05: Global human insulin market 2015-2020 ($ billions)
  • Exhibit 06: Pipeline portfolio: Global type 1 diabetes drugs market
  • Exhibit 07: Global diabetes drugs market by type of disease prevalence 2015
  • Exhibit 08: Top-selling diabetes drugs based on sales 2014 ($ billions)
  • Exhibit 09: Market share of global diabetes drugs in global pharmaceutical drugs market 2015
  • Exhibit 10: Global diabetes drugs market 2015-2020 ($ billions)
  • Exhibit 11: Market share analysis of vendors in global diabetes drugs market 2015
  • Exhibit 12: Global type 1 diabetes drugs market 2015-2020 ($ billions)
  • Exhibit 13: Five forces analysis
  • Exhibit 14: Segmentation of type 1 diabetes drugs market by drug class
  • Exhibit 15: Estimated market share of global type 1 diabetes drugs market by drug class 2020
  • Exhibit 16: Segmentation of global type 1 diabetes drugs market based on geography 2015
  • Exhibit 17: Type 1 diabetes drugs market revenue by geography 2015-2020 ($ billions)
  • Exhibit 18: Global type 1 diabetes drugs market by geography 2015-2020
  • Exhibit 19: Type 1 diabetes drugs market in Americas 2015-2020 ($ billions)
  • Exhibit 20: Type 1 diabetes drugs market in EMEA 2015-2020 ($ billions)
  • Exhibit 21: Type 1 diabetes drugs market in APAC 2015-2020 ($ billions)
  • Exhibit 22: Global type 1 diabetes drugs market: YoY growth and revenue based on geography 2015-2020
  • Exhibit 23: Impact of drivers
  • Exhibit 24: Impact of drivers and challenges
  • Exhibit 25: Revenues from sales of major products in type 1 diabetes market 2012-2014 ($ billions)
  • Exhibit 26: Novo Nordisk: Business segmentation by revenue 2015
  • Exhibit 27: Novo Nordisk: R&D expenditure 2015
  • Exhibit 28: Novo Nordisk: YoY revenue and growth rate generated from net product sales of human insulins 2012-2015 ($ billions)
  • Exhibit 29: Novo Nordisk: YoY revenue and growth rate generated from net product sales of Levemir 2012-2015 ($ billions)
  • Exhibit 30: Novo Nordisk: YoY revenue and growth rate of NovoRapid/NovoLog 2012-2015 ($ billions)
  • Exhibit 31: Novo Nordisk: Geographical split of revenues of NovoRapid/NovoLog, 2015
  • Exhibit 32: Novo Nordisk: YoY revenue and growth rate of NovoMix/NovoLog Mix 2012-2015 ($ billions)
  • Exhibit 33: Novo Nordisk: Geographical split of revenues of NovoMix/NovoLog Mix, 2015
  • Exhibit 34: Novo Nordisk: YoY revenue and growth rate generated from net product sales of new-generation insulins 2013-2015 ($ millions)
  • Exhibit 35: Novo Nordisk: Key takeaways
  • Exhibit 36: Sanofi: Business segmentation by revenue 2015
  • Exhibit 37: Sanofi: YoY revenue and growth rate of Lantus 2013-2015 ($ billions)
  • Exhibit 38: Sanofi: Lantus geographical segmentation by revenue 2015
  • Exhibit 39: Sanofi: YoY revenue and growth rate of Apidra 2013-2015 ($ millions)
  • Exhibit 40: Sanofi: YoY revenue and growth rate of Insuman 2013-2015 ($ millions)
  • Exhibit 41: Sanofi: Key takeaways
  • Exhibit 42: Eli Lilly: YoY revenue and growth rate of Humalog 2013-2015 ($ billions)
  • Exhibit 43: Eli Lilly: YoY revenue and growth rate of Humulin 2013-2015 ($ billions)
  • Exhibit 44: Eli Lilly: Key takeaways
Back to Top